Filing Details
- Accession Number:
- 0001387131-15-002579
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-08-17 17:29:54
- Reporting Period:
- 2015-08-13
- Filing Date:
- 2015-08-17
- Accepted Time:
- 2015-08-17 17:29:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
887247 | Adamis Pharmaceuticals Corp | ADMP | Pharmaceutical Preparations (2834) | 820429727 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1277431 | B Robert Rothermel | C/O Adamis Pharmaceuticals Corporation 11682 El Camino Real, Suite 300 San Diego CA 92130 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2015-08-13 | 5,000 | $3.30 | 25,000 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2015-08-14 | 2,000 | $3.40 | 27,000 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported in Column 4 is a weighted avergae price. These shares were purchased in multiple transactions at prices ranging from $3.24 to $3.30, inclusive. The reporting person undertakes to provide to Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
- The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.358 to $3.426, inclusive. The reporting person undertakes to provide to Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4.